The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

840101839768839331963a22e7-2f0b-4aa1-b3db-2c446fe0f93b9a5d6be7-eb98-4efc-a68e-8962f7242946eb2366b7-996c-4e98-83a7-09459c39c65eARGS_News_2015_7_21_General_Releases.pdfARGS_News_2015_7_17_General_Releases.pdfARGS_News_2015_7_15_General_Releases.pdf2113617457184261232015-7-21T8:30:0-4:02015-7-17T8:30:0-4:02015-7-15T8:30:0-4:0922964922609922208General ReleasesGeneral ReleasesGeneral ReleasesInaugural Members Include Distinguished Oncologists and Immunologists to Provide Perspectives in Research and Development of Individualized Immunotherapies for the Treatment of CancerFully Personalized Immunotherapy is Being Evaluated in Combination With Standard Targeted Therapy for the Treatment of Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)Argos Therapeutics Announces Formation of Scientific Advisory BoardArgos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and PreventionArgos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003106106106201520152015No Error0

Argos Therapeutics Announces Formation of Scientific Advisory Board
Read more

Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention
Read more

Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003
Read more

> More News & Events >>>

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC